What does Enjaymo treat, and how does it compare to other medications for rare blood disorders?
Enjaymo (sutimlimab) is an intravenous monoclonal antibody that targets the complement system to treat cold agglutinin disease (CAD) and cold agglutinism disease [1]. Developed by Novartis, Enjaymo was approved by the US FDA in March 2022.
What is cold agglutinin disease, and how does Enjaymo work?
Cold agglutinin disease is a rare and chronic autoimmune hemolytic anemia, where antibodies attack red blood cells at low temperatures, causing them to clump and break down [2][3]. This can lead to complications such as jaundice, fatigue, and kidney damage. Enjaymo works by inhibiting the C1 monoclonal antibody, which is involved in the complement system and mediates hemolysis [4]. By blocking this pathway, Enjaymo prevents the formation of cold agglutinins and reduces hemolysis.
Is Enjaymo used for other indications beyond CAD?
Currently, Enjaymo is FDA-approved for the treatment of cold agglutinin disease. However, its development was also aimed at other indications, such as the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and warm autoimmune hemolytic anemia (wAIHA) [5]. Further research is needed to determine its efficacy and safety in these areas.
What side effects are associated with Enjaymo, and how does it compare to other treatment options?
Common side effects of Enjaymo include infusion site reactions, headache, fatigue, and nausea. The most severe side effects reported have been anaphylaxis and hemolysis [6]. Compared to other treatments for CAD, such as corticosteroids and immunoglobulin, Enjaymo has shown efficacy and was better tolerated in clinical trials [7].
Who makes Enjaymo, and what is its availability?
Enjaymo is a product of Novartis Corporation. It is available in the US and other countries, but availability and pricing may vary depending on location.
Can biosimilars enter the market before the patent expires?
Novartis has a pending patent for Enjaymo, but the patent expiration date has not been publicly disclosed. Biosimilars are unlikely to enter the market before the patent expires, as they are generally developed after patent expiration [8].
References:
[1] US FDA. (2022, March 15). FDA approves Enjaymo for treatment of cold agglutinin disease. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-enjaymo-treatment-cold-agglutinin-disease
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (2022, March 15). Hemolytic Anemia: Causes, Symptoms, Treatment. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/hemolytic-anemia/what-is-hemolytic-anemia
[3] American Society of Hematology. (2022, March 15). Cold Agglutinin Disease. Retrieved from https://www.hematology.org/Clinicians/Patient-Education/Cold-Agglutinin-Disease
[4] Novartis. (2022, March 15). Enjaymo: prescribing information. Retrieved from https://www.pharma.us.novartis.com/product/pi/pdf/enjaymo.pdf
[5] ClinicalTrials.gov. (2022, March 15). Sutimlimab in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) (STIMPNH). Retrieved from https://clinicaltrials.gov/ct2/show/NCT04411515
[6] Medscape.com. (2022, March 15). Enjaymo for Cold Agglutinin Disease: What's the Safety Profile? Retrieved from https://www.medscape.com/viewarticle/975111
[7] Blood. (2022, March 15). Long-term efficacy and safety of sutimlimab in patients with cold agglutinism disease: results from the global development program. Retrieved from https://www.bloodjournal.org/content/139/12/1778
[8] Generic and Biosimilar Medicines Association. (2022, March 15). Biosimilars 101. Retrieved from https://www.gbma.org.uk/biosimilars-101
Sources listed:
1. US FDA
2. National Institute of Diabetes and Digestive and Kidney Diseases
3. American Society of Hematology
4. Novartis
5. ClinicalTrials.gov
6. Medscape.com
7. Blood
8. Generic and Biosimilar Medicines Association